Cargando…

COVID-19 Vaccine Platforms: Challenges and Safety Contemplations

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents aga...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Jighefee, Hadeel T., Najjar, Hoda, Ahmed, Muna Nizar, Qush, Abeer, Awwad, Sara, Kamareddine, Layla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537163/
https://www.ncbi.nlm.nih.gov/pubmed/34696306
http://dx.doi.org/10.3390/vaccines9101196
_version_ 1784588184010620928
author Al-Jighefee, Hadeel T.
Najjar, Hoda
Ahmed, Muna Nizar
Qush, Abeer
Awwad, Sara
Kamareddine, Layla
author_facet Al-Jighefee, Hadeel T.
Najjar, Hoda
Ahmed, Muna Nizar
Qush, Abeer
Awwad, Sara
Kamareddine, Layla
author_sort Al-Jighefee, Hadeel T.
collection PubMed
description The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type.
format Online
Article
Text
id pubmed-8537163
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85371632021-10-24 COVID-19 Vaccine Platforms: Challenges and Safety Contemplations Al-Jighefee, Hadeel T. Najjar, Hoda Ahmed, Muna Nizar Qush, Abeer Awwad, Sara Kamareddine, Layla Vaccines (Basel) Review The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of lives. To halt the pandemic and alleviate its impact on society, economy, and public health, the development of vaccines and antiviral agents against SARS-CoV-2 was a dire need. To date, various platforms have been utilized for SARS-CoV-2 vaccine development, and over 200 vaccine candidates have been produced, many of which have obtained the United States Food and Drug Administration (FDA) approval for emergency use. Despite this successful development and licensure, concerns regarding the safety and efficacy of these vaccines have arisen, given the unprecedented speed of vaccine development and the newly emerging SARS-CoV-2 strains and variants. In this review, we summarize the different platforms used for Coronavirus Disease 2019 (COVID-19) vaccine development, discuss their strengths and limitations, and highlight the major safety concerns and potential risks associated with each vaccine type. MDPI 2021-10-18 /pmc/articles/PMC8537163/ /pubmed/34696306 http://dx.doi.org/10.3390/vaccines9101196 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Al-Jighefee, Hadeel T.
Najjar, Hoda
Ahmed, Muna Nizar
Qush, Abeer
Awwad, Sara
Kamareddine, Layla
COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
title COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
title_full COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
title_fullStr COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
title_full_unstemmed COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
title_short COVID-19 Vaccine Platforms: Challenges and Safety Contemplations
title_sort covid-19 vaccine platforms: challenges and safety contemplations
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537163/
https://www.ncbi.nlm.nih.gov/pubmed/34696306
http://dx.doi.org/10.3390/vaccines9101196
work_keys_str_mv AT aljighefeehadeelt covid19vaccineplatformschallengesandsafetycontemplations
AT najjarhoda covid19vaccineplatformschallengesandsafetycontemplations
AT ahmedmunanizar covid19vaccineplatformschallengesandsafetycontemplations
AT qushabeer covid19vaccineplatformschallengesandsafetycontemplations
AT awwadsara covid19vaccineplatformschallengesandsafetycontemplations
AT kamareddinelayla covid19vaccineplatformschallengesandsafetycontemplations